COMMUNIQUÉS West-GlobeNewswire

Imprivata Pledges Support for CMS “Kill the Clipboard” Initiative to Simplify and Secure Patient Access to Medical Records
27/01/2026
Company commits to advancing interoperability by enabling frictionless, secure access to devices, applications, and medical records for patients and providers WALTHAM, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Imprivata [...]
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
27/01/2026
“On Track with HCM” Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone’s Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, [...]
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
27/01/2026
Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint in the pivotal, global Phase 3 DRAGON trial with 36% reduction in lesion growth (p- [...]
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
27/01/2026
VANCOUVER, Washington, Jan. 27, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody [...]
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
27/01/2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas [...]
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
27/01/2026
Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026 SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic [...]
Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
27/01/2026
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million people in the U.S. alone In prior studies, CBT-004 demonstrated an ability to modify [...]
Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome
27/01/2026
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate Self- [...]
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
27/01/2026
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial [...]
Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
27/01/2026
Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention MELBOURNE, Australia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Propanc [...]
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
27/01/2026
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: [...]
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Functional Beverage Distribution Across Canada Through Walmart Canada and McKesson Canada
27/01/2026
WESTBROOK, Maine, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced a major expansion of its FOCUSfactor ® [...]
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)
27/01/2026
- ATI-2138 Outperforms Ritlecitinib in Reversal Model of Alopecia Universalis, the Most Severe AA Phenotype - WAYNE, Pa., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage [...]
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development
27/01/2026
SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced [...]
Verano Continues Expansion of Florida Operations with the Opening of MÜV Deltona, Elevating the Company’s Retail Footprint to 83 Florida Locations and 160 Dispensaries Nationwide
27/01/2026
MÜV Deltona is located at 1670 Providence Boulevard, a busy thoroughfare with an average daily traffic count of 8,600 vehicles 1 The new Deltona dispensary complements four existing MÜV locations in Volusia County, a [...]
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
27/01/2026
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
27/01/2026
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation Fund Clinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026 MERTK-related retinitis pigmentosa affects an estimated [...]
SweetWater 420 Fest Unveils Powerhouse 2026 Lineup: Umphrey’s McGee, Thievery Corporation & Chromeo to Headline
27/01/2026
April 17-18: SweetWater’s Biggest Music Festival Returns—Tickets on Sale Now ATLANTA, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the leading craft beer brand in [...]
Zymeworks Announces Participation in Upcoming Investor Conferences
27/01/2026
VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc . (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, [...]

Pages